Neuro-Oncology

Journal

Publication Venue For

  • Mapping uncharted territory: A gene expression signature for precision glioblastoma therapeutics.  22:1713-1714. 2020
  • A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: A Neurofibromatosis Clinical Trials Consortium study.  22:1527-1535. 2020
  • Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: Conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.  22:1422-1424. 2020
  • Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.  22:1359-1367. 2020
  • A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).  22:705-717. 2020
  • A troublesome burden, the amplification of EGFR in glioblastoma!.  22:594-595. 2020
  • Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.  22:601-612. 2020
  • ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma.  22:333-344. 2020
  • The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.  21:1498-1508. 2019
  • A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases.  21:1049-1059. 2019
  • Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus..  21:837-853. 2019
  • Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR -amplified, recurrent glioblastoma: Results from an international phase I multicenter trial.  21:106-114. 2019
  • Reactive species balance via GTP cyclohydrolase i regulates glioblastoma growth and tumor initiating cell maintenance.  20:1055-1067. 2018
  • Glioma through the looking GLASS: Molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.  20:873-884. 2018
  • Hospice care, cancer-directed therapy, and Medicare expenditures among older patients dying with malignant brain tumors.  20:986-993. 2018
  • A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.  20:666-673. 2018
  • Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02..  20:546-556. 2018
  • Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report..  20:132-142. 2018
  • MerTK as a therapeutic target in glioblastoma.  20:92-102. 2018
  • Putting "multiforme" back into glioblastoma: Intratumoral transcriptome heterogeneity is a consequence of its complex morphology.  19:1570-1571. 2017
  • Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.  19:1469-1480. 2017
  • Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.  19:1481-1493. 2017
  • Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.  19:1237-1247. 2017
  • When less is better: Care of the elderly with glioblastoma.  19:879. 2017
  • Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.  19:845-852. 2017
  • Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813..  19:252-258. 2017
  • Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.  18:1622-1633. 2016
  • RBIO-05. miRNAs THAT CONFER GLIOBLASTOMA RESISTANCE: IS THE COMBINATION MERELY A SUM OF THE PARTS?.  18:vi173-vi173. 2016
  • TMOD-18. THREE-DIMENSIONAL MICROTUMORS IN PHYSIOLOGIC MICROENVIRONMENTS MAINTAIN BRAIN TUMOR INITIATING CELLS.  18:vi210-vi210. 2016
  • Creation of an NCI comparative brain tumor consortium: Informing the translation of new knowledge from canine to human brain tumor patients.  18:1209-1218. 2016
  • Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.  18:962-973. 2016
  • Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis..  18:830-839. 2016
  • MB-41INTRAVENTRICULAR ONCOLYTIC ENGINEERED HERPES SIMPLEX VIRUS PROLONGS SURVIVAL AND REDUCES SPINAL METASTASES IN MICE BEARING HUMAN GROUP 3 MEDULLOBLASTOMA.  18:iii106.1-iii106. 2016
  • PCM-07COMPARATIVE GENOMICS: THE DOG AS A TRANSLATIONAL MODEL FOR MENINGIOMA.  18:iii140.3-iii140. 2016
  • Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.  18:227-235. 2016
  • ATCT-04RETROSPECTIVE ANALYSIS OF TUMOR TREATING FIELDS (TTFIELDS) IN ADULTS WITH GLIOBLASTOMA: SAFETY PROFILE OF THE OPTUNE™ MEDICAL DEVICE IN PATIENTS WITH IMPLANTED NON-PROGRAMMABLE SHUNTS, PROGRAMMABLE SHUNTS, AND PACEMAKERS/DEFIBRILLATORS.  17:v1.4-v1. 2015
  • Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: Results of the open-label, controlled, randomized phase II CORE study.  17:708-717. 2015
  • Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy.  17:392-406. 2015
  • Development of a Sox2 reporter system modeling cellular heterogeneity in glioma.  17:361-371. 2015
  • Contemporary murine models in preclinical astrocytoma drug development.  17:12-28. 2015
  • Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.  17:1275-1283. 2015
  • Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.  17:430-439. 2015
  • Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis.  17:1220-1230. 2015
  • BM-13 * THE (F)UTILITY OF PREDICTIVE MODELS.  16:v34-v35. 2014
  • Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.  16:1541-1546. 2014
  • Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: A neurofibromatosis clinical trials consortium phase II study.  17:596-603. 2014
  • Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model.  16:1048-1056. 2014
  • Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.  16:707-718. 2014
  • Where are we now? and where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop.  16:173-178. 2014
  • Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.  15:1673-1683. 2013
  • Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.  15:1317-1329. 2013
  • NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.  15:490-496. 2013
  • CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages.  14:1037-1049. 2012
  • Initial treatment patterns over time for anaplastic oligodendroglial tumors.  14:761-767. 2012
  • Response to Weltman and Fleury Malheiros, re Lassman et al..  14:677-678. 2012
  • Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.  13:1324-1330. 2011
  • Proteomics of gliomas: Initial biomarker discovery and evolution of technology.  13:926-942. 2011
  • Gene-protein correlation in single cells.  13:880-885. 2011
  • International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.  13:649-659. 2011
  • Glycogen synthase kinase 3β inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons.  13:459-470. 2011
  • Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.  13:28-41. 2011
  • Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma.  11:357-367. 2009
  • Phase i and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.  10:608-616. 2008
  • A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.  10:182-189. 2008
  • Gene delivery into malignant glioma by infectivity-enhanced adenovirus: In vivo versus in vitro models.  9:280-290. 2007
  • High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up.  8:183-188. 2006
  • Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.  7:213-224. 2005
  • Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.  7:134-153. 2005
  • The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.  7:122-133. 2005
  • Refining the staging evaluation of pineal regoin germinoma using neuroendoscopy and the presence of preoperative diabetes insipidus.  6:127-133. 2004
  • Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11.  6:21-27. 2004
  • Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11..  6:21-27. 2004
  • Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.  2:114-119. 2000
  • Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.  1:124-137. 1999
  • International Standard Serial Number (issn)

  • 1522-8517
  • Electronic International Standard Serial Number (eissn)

  • 1523-5866